Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 10

1.

Immunogenicity and safety of a meningococcal A conjugate vaccine in Africans.

Sow SO, Okoko BJ, Diallo A, Viviani S, Borrow R, Carlone G, Tapia M, Akinsola AK, Arduin P, Findlow H, Elie C, Haidara FC, Adegbola RA, Diop D, Parulekar V, Chaumont J, Martellet L, Diallo F, Idoko OT, Tang Y, Plikaytis BD, Kulkarni PS, Marchetti E, LaForce FM, Preziosi MP.

N Engl J Med. 2011 Jun 16;364(24):2293-304. doi: 10.1056/NEJMoa1003812.

2.

MenHibrix: a new combination meningococcal vaccine for infants and toddlers.

Hale SF, Camaione L, Lomaestro BM.

Ann Pharmacother. 2014 Mar;48(3):404-11. doi: 10.1177/1060028013514375. Epub 2013 Dec 18. Review.

PMID:
24353263
3.

Group C meningococcal polysaccharide-tetanus toxoid conjugate vaccine: a meta-analysis of immunogenicity, safety and posology.

Pöllabauer EM, Petermann R, Ehrlich HJ.

Hum Vaccin. 2005 Jul-Aug;1(4):131-9. Epub 2005 Jul 13. Review.

PMID:
17012872
4.

Meningococcal quadrivalent (serogroups A, C, W135 and Y) tetanus toxoid conjugate vaccine (Nimenrix™).

Croxtall JD, Dhillon S.

Drugs. 2012 Dec 24;72(18):2407-30. doi: 10.2165/11209580-000000000-00000. Review.

PMID:
23231026
5.

Meningococcal groups C and Y and haemophilus B tetanus toxoid conjugate vaccine (HibMenCY-TT; MenHibrix(®)): a review.

Perry CM.

Drugs. 2013 May;73(7):703-13. doi: 10.1007/s40265-013-0048-9. Review.

PMID:
23649970
6.

Is a single infant priming dose of meningococcal serogroup C conjugate vaccine in the United Kingdom sufficient?

Findlow H, Borrow R.

Hum Vaccin Immunother. 2015;11(6):1501-6. doi: 10.1080/21645515.2015.1019189. Review.

7.

Community Perspectives Associated With the African PsA-TT (MenAfriVac) Vaccine Trials.

Idoko OT, Diallo A, Sow SO, Hodgson A, Akinsola A, Diarra B, Haidara FC, Ansah PO, Kampmann B, Bouma E, Preziosi MP, Enwere GC.

Clin Infect Dis. 2015 Nov 15;61 Suppl 5:S416-21. doi: 10.1093/cid/civ596. Review.

8.

Ethical Challenges and Lessons Learned During the Clinical Development of a Group A Meningococcal Conjugate Vaccine.

Martellet L, Sow SO, Diallo A, Hodgson A, Kampmann B, Hirve S, Tapia M, Haidara FC, Ndiaye A, Diarra B, Ansah PO, Akinsola A, Idoko OT, Adegbola RA, Bavdekar A, Juvekar S, Viviani S, Enwere GC, Marchetti E, Chaumont J, Makadi MF, Pallardy F, Kulkarni PS, Preziosi MP, LaForce FM.

Clin Infect Dis. 2015 Nov 15;61 Suppl 5:S422-7. doi: 10.1093/cid/civ598. Review.

9.

The Evolution of the Meningitis Vaccine Project.

Tiffay K, Jodar L, Kieny MP, Socquet M, LaForce FM.

Clin Infect Dis. 2015 Nov 15;61 Suppl 5:S396-403. doi: 10.1093/cid/civ594. Review.

10.

Challenges and Opportunities While Developing a Group A Meningococcal Conjugate Vaccine Within a Product Development Partnership: A Manufacturer's Perspective From the Serum Institute of India.

Kulkarni PS, Socquet M, Jadhav SS, Kapre SV, LaForce FM, Poonawalla CS.

Clin Infect Dis. 2015 Nov 15;61 Suppl 5:S483-8. doi: 10.1093/cid/civ500. Review.

Supplemental Content

Support Center